These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6120408)

  • 21. Letter: Prednisone in Duchenne muscular dystrophy.
    Lancet; 1975 Feb; 1(7903):397-8. PubMed ID: 46545
    [No Abstract]   [Full Text] [Related]  

  • 22. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study.
    Walter MC; Lochmüller H; Reilich P; Klopstock T; Huber R; Hartard M; Hennig M; Pongratz D; Müller-Felber W
    Neurology; 2000 May; 54(9):1848-50. PubMed ID: 10802796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of an extended baseline period in the evaluation of treatment in a longitudinal Duchenne muscular dystrophy trial.
    Madsen KS; Miller JP; Province MA
    Stat Med; 1986; 5(3):231-41. PubMed ID: 3526500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy.
    Pernice W; Beckmann R; Ketelsen UP; Frey M; Schmidt-Redemann B; Haap KP; Roehren R; Sauer M
    Klin Wochenschr; 1988 Jul; 66(13):565-70. PubMed ID: 2463406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ineffectiveness of diltiazem in Duchenne muscular dystrophy: a placebo-controlled double-blind study].
    Toifl K; Presterl E; Graninger W
    Wien Klin Wochenschr; 1991; 103(8):232-5. PubMed ID: 1907056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. X-linked recessive (Duchenne) muscular dystrophy and purine metabolism.
    Thomson WH; Smith I
    Lancet; 1976 Oct; 2(7989):805-6. PubMed ID: 61479
    [No Abstract]   [Full Text] [Related]  

  • 27. Prednisone in Duchenne muscular dystrophy.
    Drachman DB; Toyka KV; Myer E
    Lancet; 1974 Dec; 2(7894):1409-12. PubMed ID: 4140328
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of Duchenne muscular dystrophy with growth hormone inhibitors.
    Zatz M; Betti RT; Frota-Pessoa O
    Am J Med Genet; 1986 Jul; 24(3):549-66. PubMed ID: 3524231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double blind cross over trial of theophylline prophylaxis for sleep hypoxaemia in Duchenne muscular dystrophy.
    Khan Y; Heckmatt JZ
    Neuromuscul Disord; 1997 Mar; 7(2):75-80. PubMed ID: 9131646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.
    Fenichel GM; Florence JM; Pestronk A; Mendell JR; Moxley RT; Griggs RC; Brooke MH; Miller JP; Robison J; King W
    Neurology; 1991 Dec; 41(12):1874-7. PubMed ID: 1745340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respiratory muscle training in Duchenne muscular dystrophy.
    Rodillo E; Noble-Jamieson CM; Aber V; Heckmatt JZ; Muntoni F; Dubowitz V
    Arch Dis Child; 1989 May; 64(5):736-8. PubMed ID: 2658856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy.
    Bertorini TE; Palmieri GM; Griffin JW; Igarashi M; McGee J; Brown R; Nutting DF; Hinton AB; Karas JG
    Neurology; 1988 Apr; 38(4):609-13. PubMed ID: 3281058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine.
    Moxley RT; Brooke MH; Fenichel GM; Mendell JR; Griggs RC; Miller JP; Province MA; Patterson V
    Muscle Nerve; 1987 Jan; 10(1):22-33. PubMed ID: 3550455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls.
    Mendell JR; Province MA; Moxley RT; Griggs RC; Brooke MH; Fenichel GM; Miller JP; Kaiser KK; King W; Robison J
    Arch Neurol; 1987 Aug; 44(8):808-11. PubMed ID: 3115236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The use of low doses of prednisolone for the treatment of patients with Duchenne-Becker myodystrophy].
    Shakhovskaia NI; Shishkin SS; Skozobtseva LF; Shakhovskiĭ VA; Rodnikova NI; Lunga IN; Tarksh MA; Gerasimova NL; Krakhmaleva IN
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(6):23-6. PubMed ID: 10441862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selenium metabolism and supplementation in patients with muscular dystrophy.
    Jackson MJ; Coakley J; Stokes M; Edwards RH; Oster O
    Neurology; 1989 May; 39(5):655-9. PubMed ID: 2540451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glucose assimilation and the effect of insulin in x-chromosomal recessive hereditary muscular dystrophy (Duchenne type) in tolerance tests].
    Blietz RJ; Paulmann F
    Hoppe Seylers Z Physiol Chem; 1966; 347(1):35-51. PubMed ID: 5339785
    [No Abstract]   [Full Text] [Related]  

  • 38. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies.
    Folkers K; Simonsen R
    Biochim Biophys Acta; 1995 May; 1271(1):281-6. PubMed ID: 7599221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug trials in Duchenne dystrophy.
    Davenport J; Ziter F; Allsop K; Reis A
    Muscle Nerve; 1986 May; 9(4):375-6. PubMed ID: 3713742
    [No Abstract]   [Full Text] [Related]  

  • 40. Allopurinol in Duchenne muscular dystrophy.
    Castro-Gago M; Jiménez JF; Pombo M; Tojo R; Couselo JM; Peña J
    Lancet; 1980 Jun; 1(8182):1358-9. PubMed ID: 6104148
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.